[{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Y-Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Monoclonal antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"2","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"EspeRare","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"ER-004","moa":"Endogenous EDA protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-amniotic injection","sponsorNew":"Pierre Fabre \/ Pierre Fabre group","highestDevelopmentStatusID":"6","companyTruncated":"Pierre Fabre \/ Pierre Fabre group"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"ER-004","moa":"Endogenous EDA protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-amniotic injection","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Puma Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Neratinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Tablet","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Y-Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Human Antibody-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"1","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Amring Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pierre Fabre \/ Amring Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Amring Pharmaceuticals"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Tabelecleucel","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0.37,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Intravenous","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"EspeRare","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ER004","moa":"TNF receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-amniotic Injection","sponsorNew":"Pierre Fabre \/ Pierre Fabre group","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Pierre Fabre group"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Ribonexus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"K01401","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Pierre Fabre \/ Ribonexus","highestDevelopmentStatusID":"4","companyTruncated":"Pierre Fabre \/ Ribonexus"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Pierre Fabre \/ Talem Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Pierre Fabre \/ Talem Therapeutics"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"2","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"EORTC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ EORTC","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ EORTC"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"European Organisation for Research and Treatment of Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ European Organisation for Research and Treatment of Cancer","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ European Organisation for Research and Treatment of Cancer"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Pembrolizumab","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Urovant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"EspeRare","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ER004","moa":"Utero protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pierre Fabre \/ EspeRare foundation","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ EspeRare foundation"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Tabelecleucel","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0.37,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Erasca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pierre Fabre \/ Atara Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Atara Biotherapeutics"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Scorpion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"STX-721","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pierre Fabre","amount2":0.62,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.62,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"5","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Idazoxan","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Terran Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Terran Biosciences"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"VERT-002","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"5","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Vernalis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"3","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Scorpion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"STX-721","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Tabelecleucel","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0.64000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.64000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Kinnate Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Exarafenib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pierre Fabre","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vibegron","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Tabelecleucel","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0.67000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.67000000000000004,"dosageForm":"Injection","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PFL-002","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vibegron","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Scorpion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"STX-241","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Scorpion Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Pierre Fabre \/ Scorpion Therapeutics"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PFL-002","moa":"","graph1":null,"graph2":null,"graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Pierre Fabre \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Pierre Fabre
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
